Webinar
The State of Joint Clinical Assessments in Europe: Latest Developments and Implications for Manufacturer Strategy
calendar

May 22, 2024

Calendar
clock

11:00am - 12:00pm

Eastern

Register

ON-DEMAND WEBINAR

In this webinar, industry leaders will discuss the organizational implications of new evidence needs including the content and timing of evidence needed for access and reimbursement.

Key Takeaways:

  • JCA will apply to new oncology asset submissions beginning in 2025 and across all disease areas by 2030
  • JCA will significantly change the nature and timing of evidence required for HTA submission in Europe
  • JCA will require organizational adaptation
  • Coordination throughout with local teams to optimize local HTA decisions

Speakers:

Matthew Barrett
Principal, Value and Access Strategy Consulting, IQVIA

Akim Ziai
Principal, Value and Access Strategy Consulting, IQVIA

Related solutions

Contact Us